JAK2 and myeloid sarcoma: In Conti's study [23], the authors reported that both mRNA and cell surface expression of the signaling chain of the IFN-γ receptor (IFN-γR2) and its cognate tyrosine kinase JAK2 were enhanced in peripheral blood Th17 cells and clones from MS patients, compared to those with inactive multiple sclerosis or healthy controls.